Angray Kang

Professor in Immunotechnology

Queen Mary University of London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (14)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (5)

Hong Wan

Non-clinical senior lecturer

Queen Mary University of London

UNITED KINGDOM

View details

Ewan R. G. Main

University College London

UNITED KINGDOM

View details

Klaus Schmierer

PORTUGAL

View details

Emma Tallantyre

Clinical Reader

Cardiff University

UNITED KINGDOM

View details

nikos evangelou

Clinical Associate Professor of Neurology

University of Nottingham

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Angray Kang

Research Interests

Explore related searches

Contact this professor

Articles (14)

Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination

Exploring the “N-Terminal Anchor” Binding Interface of the T3SS Chaperone–Translocator Complexes from <i>P. aeruginosa</i>

Exploring the ‘N-terminal arm’ & ‘Convex surface’ Binding Interfaces of the T3SS Chaperone-Translocator Complexes from P. Aeruginosa: Exploring the T3SS PcrH-PopB/D Binding Interfaces

The impact of sphinogosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination

Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis

COVID‐19 Vaccine Response in People with Multiple Sclerosis

Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis

Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis

Induction of p53 in keratinocyte cultures treated with Behçet's patient sera

A cell-based assay for the detection of neutralizing antibodies against alemtuzumab.

GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains.

The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies.

Collaborators (5)

Hong Wan

Ewan R. G. Main

Klaus Schmierer

Emma Tallantyre

nikos evangelou

Make your next move.

Angray Kang

Research Interests

Explore related searches

Contact this professor

Articles (14)

Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis

Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination

Exploring the “N-Terminal Anchor” Binding Interface of the T3SS Chaperone–Translocator Complexes from <i>P. aeruginosa</i>

Exploring the ‘N-terminal arm’ &amp; ‘Convex surface’ Binding Interfaces of the T3SS Chaperone-Translocator Complexes from P. Aeruginosa: Exploring the T3SS PcrH-PopB/D Binding Interfaces

The impact of sphinogosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination

Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis

COVID‐19 Vaccine Response in People with Multiple Sclerosis

Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis

Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis

Induction of p53 in keratinocyte cultures treated with Behçet's patient sera

A cell-based assay for the detection of neutralizing antibodies against alemtuzumab.

GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains.

The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies.

Collaborators (5)

Hong Wan

Ewan R. G. Main

Klaus Schmierer

Emma Tallantyre

nikos evangelou

Make your next move.

Exploring the ‘N-terminal arm’ & ‘Convex surface’ Binding Interfaces of the T3SS Chaperone-Translocator Complexes from P. Aeruginosa: Exploring the T3SS PcrH-PopB/D Binding Interfaces